CAPR Company Profile and Key Details
Capricor Therapeutics, Inc.
CAPR Stock Price Chart
Stock Price Today
Capricor Therapeutics, Inc. (CAPR) stock surged +5.97%, trading at $14.90 on NASDAQ, up from the previous close of $14.06. The stock opened at $14.06, fluctuating between $13.99 and $15.78 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Company Information
| Employees | 101 |
| Beta | 4.02 |
| Sales or Revenue | $25.18M |
| 5Y Sales Change% | 0.653% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Capricor Therapeutics, Inc. (NASDAQ: CAPR) stock price is $14.90 in the last trading session. During the trading session, CAPR stock reached the peak price of $15.78 while $13.99 was the lowest point it dropped to. The percentage change in CAPR stock occurred in the recent session was 5.97% while the dollar amount for the price change in CAPR stock was $0.84.
The NASDAQ listed CAPR is part of Biotechnology industry that operates in the broader Healthcare sector. Capricor Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Deborah D. Ascheim M.D.
Consultant
Catherine Lee Kelleher
Consultant
Dr. Deborah D. Ascheim
Consultant
Mr. Xavier Avat
Chief Bus. Officer
Dr. Frank Isaac Litvack FACC, M.D.
Executive Chairman
Dr. Linda Marbán Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Anthony J. Bergmann M.B.A.
Chief Financial Officer & Corporation Treasurer
Ms. Karen G. Krasney
Executive Vice President, Gen. Counsel & Sec.
Dr. Eduardo Marbán
Co-Founder & Chairman of Scientific Advisory Board
Dr. Kristi A. H. Elliott Ph.D.
Chief Science Officer
CAPR's closing price is 323.3% higher than its 52-week low of $3.52 where as its distance from 52-week high of $23.40 is -36.33%.
Number of CAPR employees currently stands at 101.
Official Website of CAPR is: https://www.capricor.com
CAPR could be contacted at phone 310 358 3200 and can also be accessed through its website. CAPR operates from 10865 Road to the Cure, San Diego, CA 92121, United States.
CAPR stock volume for the day was 1.18M shares. The average number of CAPR shares traded daily for last 3 months was 1.28M.
The market value of CAPR currently stands at $677.50M with its latest stock price at $14.90 and 45.47M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com